TNF-Related Apoptosis-Inducing Ligand
"TNF-Related Apoptosis-Inducing Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane-protein belonging to the TNF family of intercellular signaling proteins. It is a widely expressed ligand that activates APOPTOSIS by binding to TNF-RELATED APOPTOSIS-INDUCING LIGAND RECEPTORS. The membrane-bound form of the protein can be cleaved by specific CYSTEINE ENDOPEPTIDASES to form a soluble ligand form.
| Descriptor ID |
D053221
|
| MeSH Number(s) |
D12.644.276.374.750.625 D12.776.467.374.750.625 D23.529.374.750.625
|
| Concept/Terms |
TNF-Related Apoptosis-Inducing Ligand- TNF-Related Apoptosis-Inducing Ligand
- Apoptosis-Inducing Ligand, TNF-Related
- TNF Related Apoptosis Inducing Ligand
- Apo-2 Ligand
- Apo 2 Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 10
- Apo-2L Protein
- Apo 2L Protein
- TNF Superfamily, Member 10
- CD253 Antigen
- Antigen, CD253
- TRAIL Protein
|
Below are MeSH descriptors whose meaning is more general than "TNF-Related Apoptosis-Inducing Ligand".
Below are MeSH descriptors whose meaning is more specific than "TNF-Related Apoptosis-Inducing Ligand".
This graph shows the total number of publications written about "TNF-Related Apoptosis-Inducing Ligand" by people in this website by year, and whether "TNF-Related Apoptosis-Inducing Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "TNF-Related Apoptosis-Inducing Ligand" by people in Profiles.
-
Guimar?es PPG, Gaglione S, Sewastianik T, Carrasco RD, Langer R, Mitchell MJ. Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. ACS Nano. 2018 02 27; 12(2):912-931.
-
Mitchell MJ, Webster J, Chung A, Guimar?es PP, Khan OF, Langer R. Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis. Nat Commun. 2017 03 20; 8:14179.
-
Wayne EC, Chandrasekaran S, Mitchell MJ, Chan MF, Lee RE, Schaffer CB, King MR. TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer. J Control Release. 2016 Feb 10; 223:215-223.
-
Mitchell MJ, King MR. Unnatural killer cells to prevent bloodborne metastasis: inspiration from biology and engineering. Expert Rev Anticancer Ther. 2014 Jun; 14(6):641-4.
-
Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):930-5.
-
Shrestha B, Pinto AK, Green S, Bosch I, Diamond MS. CD8+ T cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons. J Virol. 2012 Sep; 86(17):8937-48.
-
Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, Gilbert CA, Ross AH, Plescia J, Altieri DC. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 2011 Apr; 121(4):1349-60.
-
Feng X, Yan J, Wang Y, Zierath JR, Nordenskj?ld M, Henter JI, Fadeel B, Zheng C. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol. 2010 Aug; 47(14):2388-96.
-
Cho YS, Challa S, Clancy L, Chan FK. Lipopolysaccharide-induced expression of TRAIL promotes dendritic cell differentiation. Immunology. 2010 Aug; 130(4):504-15.
-
Lu Q, Lu C, Zhou GP, Zhang W, Xiao H, Wang XR. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol Oncol. 2010 Nov-Dec; 28(6):635-41.